Tirzepatide: what the published research shows
A research-focused summary of published and registered studies on tirzepatide (LY3298176), a dual GLP-1 and GIP receptor agonist, covering obesity, diabetes, endometrial hyperplasia, postbariatric hypoglycemia, CCCA, and
Tirzepatide (also known as LY3298176) is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors [6]. It is the active pharmaceutical ingredient in the research compound Tirzepatide. The evidence block for this page does not provide sequence, molecular formula, or molecular weight; those identifiers are therefore not reported here. The published and registered research summarised below centres on the GLP-1 and GIP receptor pathway and its downstream effects on appetite, gastric emptying, glycaemic control, and weight regulation [6][8].
Studies in the evidence block span randomised preoperative optimisation, phase II and single-arm oncology-adjacent trials, real-world observational cohorts, a case series, and mechanistic investigations. Several are ongoing or not yet reported; where that is the case, the text says so. No human dose, clinical recommendation, or outcome promise is made on this page.
Research Studies
Tirzepatide and preoperative optimisation before one anastomosis gastric bypass
A registered trial compares three preoperative strategies before one anastomosis gastric bypass (OAGB) for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care [1]. The primary goal is to determine which approach produces the best weight loss one year after surgery. Secondary evaluations include safety, surgical outcomes, and improvement of obesity-related conditions such as diabetes, high blood pressure, and sleep apnea [1]. The study is registered on ClinicalTrials.gov and, at the time of writing, has not reported results.
Tirzepatide and progestin intrauterine device in endometrial hyperplasia and grade 1 endometrial cancer
A phase II trial investigates whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response — the absence of cancer cells in tissue samples after treatment — in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese [2]. The background notes that endometrial cancer occurrence has continued to rise in the United States, and that over half of cases are thought to be attributable to being overweight and obese, with a weight-dependent risk relationship [2]. AH/EIN is described as a precancerous condition of the endometrium [2]. This trial is registered and ongoing.
Tirzepatide and levonorgestrel IUD therapy for EIN and early-stage endometrial cancer
A separate single-arm study evaluates the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard LNG-IUD therapy in patients with endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid endometrial carcinoma with co-existing obesity and metabolic risk factors [3]. Participants receive tirzepatide once weekly while continuing standard clinical management with an LNG-IUD; treatment decisions remain at the discretion of the treating physician [3]. The primary objective is pathologic response at approximately 6 months, with secondary objectives including changes in metabolic parameters [3]. This study is registered and ongoing.
Tirzepatide in Pakistani adults with obesity, prediabetes, and type 2 diabetes
A multicentre, prospective, observational study examines tirzepatide as used in routine clinical care in Pakistan [4]. The background states that tirzepatide is already approved for type 2 diabetes and for obesity, but that there is very little information on how it works for people in South Asia, and none from Pakistan specifically [4]. The study will follow 330 adults starting tirzepatide as part of normal treatment across ten diabetes and endocrinology centres in Pakistan. All participants have obesity and are grouped into three cohorts based on blood sugar status at the start: obesity without diabetes, prediabetes with obesity, and type 2 diabetes [4]. This observational study is registered and ongoing.
Tirzepatide and central centrifugal cicatricial alopecia (CCCA)
A pilot clinical trial investigates whether tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults [5]. The main questions are whether tirzepatide improves the symptoms and signs of active CCCA, whether it changes the activity of genes in the scalp (especially genes related to scarring), and whether it promotes hair regrowth [5]. Participants inject tirzepatide once a week for 12 months, attend clinic visits for scalp examinations, photographs, and other health assessments, undergo scalp biopsies at the beginning of the study and after 6 months of treatment, and have blood tests [5]. This trial is registered and ongoing.
Tirzepatide and postbariatric hypoglycemia after Roux-en-Y gastric bypass
A case series describes 3 patients with postbariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass who were treated with tirzepatide [6]. All patients presented with symptomatic hypoglycemia characterised by episodes of diaphoresis, visual disturbances, confusion, and documented low blood glucose levels occurring postprandially [6]. Conventional management strategies, including dietary modifications, acarbose, and other pharmacotherapies, were either partially effective or limited by side effects [6]. The report describes initiation of tirzepatide in this context [6]. This is a small case series, not a controlled trial; findings are hypothesis-generating and should not be generalised.
Tirzepatide and ileal pouch-anal anastomosis with chronic high bowel frequency
A clinical trial investigates whether tirzepatide (Zepbound) can decrease bowel frequency in patients who have an ileal pouch-anal anastomosis (IPAA or pouch) better than standard-of-care anti-diarrhoeal therapy [7]. The main question is whether tirzepatide reduces bowel frequency better than standard of care in this population [7]. Participants visit the clinic 5 times, answer questions about symptoms daily, are assigned to take the study product as instructed, and provide a stool sample 4 times [7]. This trial is registered and ongoing.
Tirzepatide and gastric emptying in type 1 diabetes with overweight or obesity
A study of tirzepatide (LY3298176) in participants with type 1 diabetes mellitus (T1DM) and overweight or obesity aims to learn more about how tirzepatide affects stomach emptying [8]. Participation lasts about 8 weeks, including screening and follow-up [8]. This study is registered and ongoing.
Tirzepatide in early uncontrolled type 2 diabetes: comparative evidence
A reference-only source reports that in adults with early uncontrolled type 2 diabetes, tirzepatide versus intensified conventional care reduced HbA1c levels and weight at 2 years [10]. This finding is reported here as a fact from the cited paper; the full text is not reproduced. The evidence block does not provide effect sizes or confidence intervals for this comparison.
Tirzepatide discontinuation and weight regain trajectories
A reference-only reconstructed aggregate-data Bayesian longitudinal meta-analysis examined weight regain trajectories after discontinuation of semaglutide or tirzepatide [11]. The background states that both agents produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain; the objective was to estimate post-discontinuation weight-regain trajectories and explore predictors of faster regain [11]. This finding is reported as a fact from the cited paper; the full text is not reproduced.
Tirzepatide and major cardiovascular events: comparative effectiveness
A reference-only comment discusses comparative effectiveness of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease, based on two target-trial emulations [12]. This finding is reported as a fact from the cited paper; the full text is not reproduced. The evidence block does not provide numerical results.
Tirzepatide and oral health: emerging implications
A reference-only paper addresses emerging oral health implications for oral medicine practice in relation to tirzepatide [9]. This finding is reported as a fact from the cited paper; the full text is not reproduced. The evidence block does not provide specific oral health outcomes.
Summary of study designs in the evidence block
| Study | Design | Population | Primary focus |
|---|---|---|---|
| [1] | Randomised preoperative optimisation | Severe obesity undergoing OAGB | Weight loss at 1 year; safety; surgical outcomes |
| [2] | Phase II trial | Women with AH/EIN or grade 1 endometrial cancer, overweight or obese | Pathologic response with LNG-IUD |
| [3] | Single-arm study | EIN or grade 1 endometrioid endometrial carcinoma with obesity and metabolic risk factors | Pathologic response at ~6 months; metabolic parameters |
| [4] | Multicentre prospective observational | 330 adults in Pakistan with obesity, prediabetes, or type 2 diabetes | Real-world outcomes |
| [5] | Pilot clinical trial | Adults with active CCCA | Symptoms/signs; scalp gene activity; hair regrowth |
| [6] | Case series (3 patients) | Postbariatric hypoglycemia after Roux-en-Y gastric bypass | Symptomatic hypoglycemia |
| [7] | Clinical trial | Patients with IPAA and chronic high bowel frequency | Bowel frequency vs standard anti-diarrhoeal therapy |
| [8] | Clinical study | Type 1 diabetes with overweight or obesity | Gastric emptying |
| [10] | Reference-only comparative report | Adults with early uncontrolled type 2 diabetes | HbA1c and weight at 2 years |
| [11] | Reference-only meta-analysis | Post-discontinuation of semaglutide or tirzepatide | Weight regain trajectories |
| [12] | Reference-only target-trial emulations | Type 2 diabetes and cardiovascular disease | Major cardiovascular events |
| [9] | Reference-only oral medicine paper | Not specified in evidence block | Oral health implications |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery
- [2] A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- [3] Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
- [4] Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
- [5] Tirzepatide for Treatment of CCCA
- [6] Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
- [7] Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
- [8] A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
- [9] Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice.
- [10] In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y.
- [11] Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
- [12] Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.